Dupilumab for atopic children with eosinophilic esophagitis: A case series
Journal of Allergy and Hypersensitivity Diseases · 2025
DOI: 10.1016/j.jahd.2025.100034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Hypersensitivity Diseases, 2025. Verfasst von Alireza Maleki und 6 weiteren Autor:innen. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AXA Research Fund.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
• Eosinophilic esophagitis in atopic children may respond well to dupilumab. • This study highlights the multi-faceted impact of dupilumab on atopic disease. • Holistic management of atopic disease benefits from targeting the type 2 pathway. • Dupilumab can be considered in a holistic approach to managing atopic disease. The holistic management of atopic diseases and allergic diseases has gained significant relevance with the recent discovery of the role of type 2 inflammation, which links these two entities, and the development of new biotherapies targeting this pathway. Eosinophilic esophagitis is a chronic inflammatory condition of the esophagus. Since eosinophilic esophagitis involves type 2 inflammation through IL-4 and IL-13 pathways, dupilumab offers a promising therapeutic option. In this case series, we reviewed five pediatric atopic patients, aged between 7 and 17 years, with asthma or atopic dermatitis, who received dupilumab for these conditions and were also affected by eosinophilic esophagitis. We found that dupilumab was effective in all atopic manifestation, including achieving complete clinical, eosinophilic esophagitis endoscopic improvements in all patients and complete histological improvement in 60 % of the patients. Our current study confirms a good efficacy of dupilumab, in the holistic management of atopic young pediatric patients with atopic disease including eosinophilic esophagitis.
Förderung
- AXA Research Fund
Zitieren
APA
Maleki, A., Willot, S., Lioger, B., Guan-Zhide, V., Blin, M., Hoppe, A., & Hoarau, C. (2025). Dupilumab for atopic children with eosinophilic esophagitis: A case series. Journal of Allergy and Hypersensitivity Diseases. https://doi.org/10.1016/j.jahd.2025.100034
Vancouver
Maleki A, Willot S, Lioger B, Guan-Zhide V, Blin M, Hoppe A, et al. Dupilumab for atopic children with eosinophilic esophagitis: A case series. Journal of Allergy and Hypersensitivity Diseases. 2025. doi:10.1016/j.jahd.2025.100034
BibTeX
@article{Maleki2025,
author = {Maleki, Alireza and Willot, Stéphanie and Lioger, Bertrand and Guan-Zhide, Victor and Blin, Mélanie and Hoppe, Anne and Hoarau, Cyrille},
title = {Dupilumab for atopic children with eosinophilic esophagitis: A case series},
journal = {Journal of Allergy and Hypersensitivity Diseases},
year = {2025},
doi = {10.1016/j.jahd.2025.100034}
}
EUVIMED